Holen Sie sich die Stockscreener-App
1.07
0.94%
0.01
Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Lineage Cell Therapeutics Q3 EPS Reduced by HC Wainwright - MarketBeat
Lineage Cell Therapeutics Q2 Earnings Call Highlights - MarketBeat
CCORF Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Lineage Cell Therapeutics, Inc. (LCTX) stock price, news, quote and history - Yahoo Finance Australia
Lineage Cell Therapeutics Balances Progress and Risk - TipRanks
Lineage Cell Therapeutics (LCTX) Stock Faces Cash Burn Despite Paper Profit - Sahm
Lineage Cell Therapeutics Inc (LCTX) Stock News Today - tradingkey.com
Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Hig - GuruFocus
LCTX Looks 13.7% Undervalued on GF Value™ - GuruFocus
Transcript : Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Earnings call transcript: Lineage Cell Therapeutics posts Q2 2026 profit, extends runway - Investing.com
Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Lineage Cell: Q2 Earnings Snapshot - marketscreener.com
[10-Q] Lineage Cell Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Lineage Cell Therapeutics (LCTX) Holds Above $1.07 Support as Biotech ConsolidatesFloat Adjusted Cap - dars.gov.et
3 Penny Stocks With Market Caps Larger Than $40M To Watch - webull.com
Lineage Cell Therapeutics, Inc. Revenue Breakdown – AMEX:LCTX - TradingView
Earnings Preview: LCTX to Report Financial Results Post-market on August 06 - Moomoo
Lineage Cell Therapeutics to announce Q2 2026 results on August 6 with business update call - Traders Union
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 - Yahoo Finance
BlackRock, Inc. (LCTX) discloses 5.3% beneficial ownership in Lineage Cell - Stock Titan
Lineage Cell Therapeutics Inc (LCTX) Income Statement - tradingkey.com
Lineage Cell Therapeutics Inc (LCTX) Cash Flow - TradingKey
Lineage Cell Therapeutics Inc - TradingKey
LCTX|Lineage Cell Therapeutics Inc|Price:1.035|Chg%:+0.005 - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Balance Sheet - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lineage Cell Therapeutics (LCTX) Slips 3.74% as Stock Tests Key Support LevelsOBV Trend Line - dars.gov.et
Lineage Cell Therapeutics, Inc. Revenue Breakdown – SWB:BT3 - TradingView
Lineage Cell Therapeutics, Inc. Revenue Breakdown – LS:A2PP89 - TradingView
LCTX|Lineage Cell Therapeutics Inc|Price:1.030|Chg%:-0.035 - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OpRegen regenerative medicine program showcased at major vision event by Lineage Cell Therapeutics - Traders Union
Lineage Cell Therapeutics (LCTX) Edges Lower as Stock Hovers Near Key SupportFibonacci Retracement - dars.gov.et
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating - Moomoo
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan - Yahoo Finance
Lineage Cell advances corneal cell therapy program to animal testing - Investing.com
Lineage Cell advances corneal cell therapy program to animal testing By Investing.com - Investing.com Nigeria
Lineage Cell Therapeutics advances COR1 preclinical program for corneal endothelial disease - Traders Union
Lineage Cell Therapeutics Provides Update On COR1 Cell Therapy Program For Corneal Endothelial Disease - marketscreener.com
Lineage Cell Updates on COR1 for Corneal Endothelial Disease Tre - GuruFocus
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease - Business Wire
New COR1 cell therapy aims to ease global shortage of corneal transplants - Stock Titan
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit - BioSpace
Lineage Cell Therapeutics, Inc. Actuals & Estimates (AMEX:LCTX) - TradingView
Price to book forward of Lineage Cell Therapeutics, Inc. – AMEX:LCTX - TradingView
Price to earnings forward of Lineage Cell Therapeutics, Inc. – AMEX:LCTX - TradingView
Price to sales forward of Lineage Cell Therapeutics, Inc. – AMEX:LCTX - TradingView
Lineage Cell Therapeutics Q1 2026 Earnings: EPS Falls Short Amid Continued R&D InvestmentBalance Sheet Strength - dars.gov.et
LCTX Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock ReactionShare Dilution Risk - dars.gov.et
LCTXLineage Cell Therapeutics Inc Stock Price and Quote - Finviz
Form 4 Lineage Cell Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Lineage Cell (LCTX) director granted 125,000 options at $1.30 strike - Stock Titan
Lineage Cell (LCTX) awards director Deborah Andrews 125K stock options - Stock Titan
Lineage Cell Therapeutics (LCTX) director awarded 125,000 stock options at $1.30 - Stock Titan
Lineage Cell Therapeutics (LCTX) director granted 125,000 options at $1.30 strike - Stock Titan
Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call - Benzinga
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):